Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, announced on April 13th that it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management. Also participating in the round were ARCH Venture Partners, co-founded by Robert Nelsen and one of the largest early-stage technology venture firms in the United States, Goldman Sachs, and Nolan Capital, the investment fund of former AveXis CEO and current Jaguar Executive Chairman Sean P. Nolan. Led by former AveXis leadershipJaguar leverages a proven management team with the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments for patients suffering from severe genetic diseases, including galactosemia, genetic causes of autism spectrum disorder, Type 1 diabetes and Bardet-Biedl syndrome.

For further information, see Jaguar Therapeutics (https://jaguargenetherapy.com/news/jaguar-gene-therapy-closes-139-million-series-b-funding-co-led-by-eli-lilly-and-company-and-deerfield-management)

Leave a Reply

Your email address will not be published. Required fields are marked *